Rosen Law Firm Initiates Class Action Investigation for Immutep Ltd. Investors

Overview

The Rosen Law Firm, a prominent global law firm specializing in investor rights, is actively conducting an investigation into possible securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP). This investigation follows alarming events wherein Immutep Ltd. is accused of misleading the investing public with potentially inaccurate statements about its business operations.

Background on Immutep Ltd.

On March 13, 2026, the landscape shifted dramatically for Immutep Ltd. when they issued a press release concerning their TACTI 004 Phase III trial. This clinical trial was assessing the efficacy of their product, eftilagimod alfa, in patients suffering from non-small cell lung cancer. The Independent Data Monitoring Committee (IDMC) assessed the study and recommended its discontinuation based on a planned interim futility analysis, which indicated that the study would not yield the expected results.

The aftermath of this announcement was significant; the price of Immutep's American Depositary Receipts (ADRs) plummeted by $2.28—an alarming 82.6%—closing at just $0.48. This substantial decline has led to concerns among investors, prompting the inquiry into whether they may be entitled to recover their losses.

What Investors Should Know

Investors who purchased shares of Immutep Ltd. might be eligible for compensation under a contingency fee arrangement, meaning they wouldn’t pay any upfront costs to pursue a class action lawsuit. The Rosen Law Firm is preparing legal action aiming to reclaim financial losses for affected investors.

If you believe you have a claim, you can join the class action by visiting Rosen Legal or by calling Phillip Kim, Esq. toll-free at 866-767-3653. For further information, you can also email [email protected].

Leadership in Securities Litigation

The Rosen Law Firm emphasizes the importance of selecting a legal counsel with a proven history in handling such cases. Many firms that issue notices may lack the necessary experience, resources, and recognition to effectively manage securities class actions. Unlike other law firms, the Rosen Law Firm has successfully led numerous high-profile securities cases, including a record-breaking settlement against a Chinese company.

Having secured over $438 million for investors in 2019 alone and consistently ranking among the top for securities class action settlements, the firm stands as a trustworthy choice for investors seeking legal recourse. Its founding partner, Laurence Rosen, has earned significant accolades from reputable sources like Law360 and Lawdragon, further solidifying the firm's reputation.

Conclusion

For investors in Immutep Ltd. feeling uncertain after the recent drastic drop in share price, now is a crucial time to consider your legal options. With the ongoing investigation by the Rosen Law Firm, you may have the opportunity to recover your losses. Stay updated by following the firm on LinkedIn, Twitter, and Facebook for the latest developments in this unfolding situation.

Contact Information
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

Attorney Advertising. Past results do not guarantee a similar outcome.